Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a nebulized cocktail make lung scopes less Cough-Inducing?

NCT ID NCT07743333

Symptom relief Sponsor: Alexandria University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests whether adding nebulized ketamine to lidocaine before a fiberoptic bronchoscopy reduces coughing and discomfort compared to lidocaine alone or standard spray. About 134 adults scheduled for bronchoscopy will receive one of three premedication approaches. The study tracks cough severity, patient tolerance, satisfaction, and safety, including blood pressure and oxygen levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nebulized lidocaine and ketamine
What this could lead to
If effective, this combination could make bronchoscopy more comfortable and safer, reducing coughing and improving patient tolerance during the procedure.
What could go wrong
This is a single-center trial with a modest number of participants, and the added benefit of ketamine may be small or come with side effects like sedation or blood pressure changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

134 people

The number who actually took part.

Started

Sep 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients were assigned for FOB for diagnostic causes as part of their usual care. * All patients were assigned for FOB for therapeutic causes as part of their usual care. Exclusion Criteria: * unstable angina or recent myocardial infarction, * hypoxemia that is not corrected by oxygen therapy, * increased intracranial pressure or recent cerebrovascular stroke, * uncontrolled uraemia, * uncontrolled hypertension, * current viral infections or colds, * history of allergy to lidocaine or ketamine, * altered mental status, or * non-corrected coagulopathy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fiberoptic bronchoscopy (FOB) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fiberoptic bronchoscopy (FOB) Lung cancer (diagnosis) Premedication

Contacts and locations

Locations

  • Alexandria University Faculty of Medicine

    Alexandria, Alexandria Governorate, 21526, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.